↓ Skip to main content

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Overview of attention for article published in BMC Cancer, May 2022
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
3 X users

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
Published in
BMC Cancer, May 2022
DOI 10.1186/s12885-022-09478-4
Pubmed ID
Authors

Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 14%
Unspecified 1 7%
Student > Bachelor 1 7%
Researcher 1 7%
Lecturer 1 7%
Other 0 0%
Unknown 8 57%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 21%
Unspecified 1 7%
Agricultural and Biological Sciences 1 7%
Engineering 1 7%
Unknown 8 57%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2022.
All research outputs
#12,890,747
of 22,738,543 outputs
Outputs from BMC Cancer
#2,710
of 8,272 outputs
Outputs of similar age
#169,922
of 438,155 outputs
Outputs of similar age from BMC Cancer
#51
of 291 outputs
Altmetric has tracked 22,738,543 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,272 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,155 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 291 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.